Hybrid Recanalization for the Treatment of Carotid/Vertebral In-stent Restenosis or Occlusion: Pilot Surgery Experiences From One Single Center

Chao Wang1,2,3,4, Peng Zhao4, Tao Sun1,4, Mengtao Han1,4, Yunyan Wang4, Wei Wu5, Xingang Li1,4* and Donghai Wang1,4*

1 School of Clinical Medicine, Shandong University, Jinan, China, 2 Dezhou City People's Hospital, Dezhou, China, 3 Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, China, 4 Department of Neurosurgery, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China, 5 Department of Neurology, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China

Background: The hybrid recanalization of internal carotid artery (ICA) and vertebral artery (VA) in-stent restenosis or occlusion using a combination of endarterectomy and endovascular intervention has achieved technical success. We present our surgical experiences to further evaluate the safety and efficacy of the hybrid technique for the treatment of in-stent restenosis and occlusion.

Methods: A cohort of 12 refractory patients with in-stent restenosis or occlusion who underwent hybrid recanalization, a combination of endarterectomy and endovascular intervention, were retrospectively analyzed. Medical records, including presenting symptoms, comorbidities, contralateral ICA/VA findings, use of antiplatelet drugs, postoperative complications, and angiographic outcomes, were collected.

Results: Among 415 consecutive patients with ICA, common carotid artery, and V1 segment lesions, 12 refractory patients (2.89%) with 13 cases were enrolled in our study (1 female and 11 male). All patients underwent successful hybrid recanalization. There were no cases of postoperative stroke or death. Only two patients sustained hoarseness, but it resolved within 2 weeks after surgery. Three patients were treated with dual antiplatelet (aspirin and clopidogrel), seven with single antiplatelet (aspirin), one with single antiplatelet (clopidogrel), and one with single antiplatelet (ticagrelor). All patients were followed up in the outpatient department according to the protocol, with a mean follow-up period of 13 months (range, 6–24 months). No death or recurrent symptoms occurred during the regular follow-up period.

Conclusion: The hybrid technique maybe a safe and feasible treatment option to recanalize in-stent restenosis or occlusion with acceptable complications.

Keywords: endarterectomy, hybrid recanalization, occlusion, restenosis, stent
INTRODUCTION

Stroke derived from carotid or vertebral artery stenosis or occlusion poses a major problem worldwide and is associated with a high risk of recurrence and poor outcome. Although stent implantation in the carotid or vertebral stenosis has been acknowledged as a safe option for reducing long term stroke risk, high rates of stroke recurrence due to in-stent restenosis (ISR) and occlusion (ISO) after carotid artery stenting (CAS; 5–11%) or vertebral artery stenting (VAS; 18–43%) have been reported (1–4). Different treatment strategies, including pharmacological therapy, endovascular therapy, and surgery, are applied for the revascularization of ISR or ISO; however, no optimal therapeutic approach is recommended at present (2, 5). To our knowledge, hybrid techniques are less utilized mainly because of the high demand for hybrid operation rooms and neurosurgeons (6, 7). Moreover, previous studies of hybrid revascularization are mainly limited to an article on the chronically occluded internal carotid artery and to case reports of VA ISO or ICA ISR (3, 6, 8, 9). Therefore, in this single-center study, the pilot experiences of hybrid recanalization in 12 patients with 13 cases of carotid/vertebral ISR or ISO were reported.

METHODS

Patients

From October 2016 to June 2020, 415 consecutive patients with internal carotid artery (ICA) and V1 segment stenosis or occlusion were admitted to our center for ischemic stroke. Written informed consent was obtained from the individuals for the publication of any potentially identifiable images or data included in this article. All patients underwent digital subtraction angiography (DSA) to confirm the lesion. Medical treatment including single antiplatelet therapy (aspirin 100 mg/d, clopidogrel 75 mg/d, or ticagrelor 180 mg/d for 90 days) plus statin and the management of risk factors (e.g., hypertension, diabetes, and lifestyle) was performed. In this study, patients were included if they met the following criteria: (1) ISR (≥70%) or occlusion of the ICA, the common carotid artery (CCA), or the V1 verified by DSA; (2) recurrent strokes or transient ischemic attacks (TIA) refractory to best medical treatment; (3) primary treatment performed using stent angioplasty; (4) available clinical and angiographic follow-up data after primary treatment and after hybrid recanalization for ISR or ISO. Exclusion criteria were: (1) lack of clinical or imaging information and (2) primary treatment only performed using balloon angioplasty or endarterectomy.

Hybrid Revascularization Technique

Under general anesthesia, transfemoral access was performed first. Then, a standard carotid endarterectomy (CEA) or vertebral endarterectomy (VEA) surgery was performed to remove the plaque with the stent. After endarterectomy, a continuous suture was performed if there was retrograde blood flow. In case of no bleeding, a Fogarty balloon (4F for CEA/3F for VEA) thrombectomy was performed through the exposed proximal ICA or V1 segment to remove the distal thrombus. Then, a balloon-expandable (for VA) or self-expanding (for ICA and CCA) stent was implanted if there was distal stenosis or dissection through rechecked angiography.

Abbreviations: ICA, internal carotid artery; VA, vertebral artery; ISR, in-stent restenosis; ISO, in-stent occlusion; CAS, carotid artery stenting; VAS, vertebral artery stenting; DSA, digital subtraction angiography; CCA, common carotid artery; TIA, transient ischemic attacks; CEA, carotid endarterectomy; VEA, vertebral endarterectomy; CTA, CT angiography; IPH, intraplaque hemorrhage; PICA, posterior inferior cerebellar artery; PSV, Peak systolic velocity; EDV, end-diastolic velocity.
TABLE 1 | Baseline characteristics, clinical data, and outcomes.

| No | Sex/age (years) | Recurrent symptoms | Smoking history | Hypertension | Hyperlipidaemia | Coronary heart disease | Diabetes | ISR/ISO type | Period from stenting to recurrence (month) | Contralateral ICA/VA | Additional endovascular device | Postoperative complications | Plaque topography and composition | Antiplatelet drugs | CTA follow-up | Follow-up time (month) |
|----|-----------------|--------------------|-----------------|--------------|----------------|----------------------|----------|--------------|------------------------------------------|----------------------|------------------------|-----------------------------|--------------------------------|---------------------|---------------|-----------------------------|
| 1  | M/60            | Limb weakness, slurred speech | –                | +            | –              | –                    | –        | –            | 30                                       | CAS-ISO              | ICA occlusion          | Balloon, stent               | None                          | Aspirin, clopidogrel       | Normal         | 6                           |
| 2  | M/66            | Limb numbness       | +                | +            | –              | –                    | +        | –            | 8                                        | CAS-ISR              | ICA moderate stenosis    | None                         | None                          | Aspirin               | Normal         | 12                          |
| 3  | M/79            | Limb weakness       | –                | +            | –              | –                    | –        | –            | 14                                       | Normal               | None                   | None                         | Aspirin, clopidogrel       | Aspirin, low grade stenosis | Normal         | 16                          |
| 4  | M/75            | Limb numbness, syncope | –                | +            | –              | –                    | –        | –            | 26                                       | Normal               | None                   | None                         | Aspirin, clopidogrel       | Normal               | 24                          |
| 5  | F/70            | Limb numbness, slurred speech | –                | –            | –              | –                    | –        | –            | 5                                        | CAS-ISR              | Normal                 | None                         | Aspirin, low grade stenosis | Normal               | 24                          |
| 6  | M/62            | Limb weakness, slurred speech | –                | +            | –              | –                    | +        | –            | 7                                        | Normal               | None                   | None                         | Eccentric, proximal stent fracture | Ticagrelor           | Normal         | 6                           |
| 7  | M/67            | Limb numbness       | +                | +            | –              | +                    | +        | –            | 19                                       | Normal               | None                   | None                         | Eccentric, proximal stent fracture | Aspirin              | Normal         | 6                           |
| 8  | M/69            | Limb weakness       | –                | –            | –              | –                    | –        | –            | 10                                       | Normal               | None                   | None                         | Eccentric, proximal stent fracture | Aspirin              | Normal         | 6                           |
| 9  | M/54            | Dizziness, walking instability | +                | +            | –              | –                    | –        | –            | 5                                        | VA dominance, PICA deficiency | None                   | Hoarseness                  | Concentric, long-segmental | Aspirin               | Normal         | 22                          |
| 10 | M/65            | Dizziness, slurred speech | –                | +            | –              | –                    | –        | –            | 5                                        | VA dominance, PICA deficiency | None                   | Hoarseness                  | Concentric, long-segmental | Aspirin               | Normal         | 12                          |
| 11 | M/70            | Dizziness           | –                | +            | –              | –                    | –        | –            | 10                                       | V4 mild stenosis       | Stent                  | None                         | Concentric, long-segmental | Aspirin, clopidogrel       | Normal         | 12                          |
| 12 | M/44            | Transient dizziness, limb numbness | +                | +            | +              | +                    | +        | –            | 3                                        | CAS-ISR, VAS-ISO       | Normal                 | Balloon, stent               | None                          | Aspirin, clopidogrel       | Normal         | 6                           |

CAS, carotid artery stenting; ICA, internal carotid artery; ISO, in-stent occlusion; ISR, in-stent restenosis; VAS, vertebral artery stenting; VA, vertebral artery.
FIGURE 1 | (A) Severe stenosis of the left proximal internal carotid artery (ICA) was observed in the digital subtraction angiography (DSA). (B) Revascularization was achieved with balloon and stent angioplasty. (C) DSA showed recurrent left proximal common carotid artery (CCA) occlusion at the 30 months follow-up (red arrow). (D) Intraoperative angiography demonstrated that complementary inflow was reconstituted by collaterals from right lingual branches (red arrow). (E) Another (Continued)
clopidogrel), seven with single antiplatelet (aspirin), one with single antiplatelet (clopidogrel), and one with single antiplatelet (ticagrelor). All patients were followed-up in the outpatient department according to the protocol, with a mean follow-up period of 13 months (range, 6–24 months). Only two patients showed a low grade stenosis (<30%), and the rest remained a normal luminal diameter after rechecking the latest imaging (CTA) follow-up. No death or recurrent symptoms occurred during the regular follow-up period. The clinical data and outcomes are summarized in Table 1.

**Topography and Composition of the Plaque**
Postoperative plaque topography (eccentric/concentric, proximal/long-segmental lesion) and morphology (stent fracture) were recorded. Plaque topography revealed eccentric plaques in eight (66.67%) CAS cases and proximal plaques in eight (66.67%) CAS cases. However, VAS cases were more prone to concentric and long-segmental lesions. Plaque morphology revealed stent fracture in one (8.33%) CAS case.

**Representative Case Illustrations**

**Patient 1**
A 60-year-old man presented with dizziness. He additionally demonstrated paroxysmal limb weakness and slurred speech despite the best pharmacological option. DSA demonstrated occlusion of the left CCA 30 months after CAS (Figures 1A–C). CCA was reconstituted by collaterals from the contralateral lingual and ipsilateral occipital branches (Figures 1D,E). He underwent successful hybrid recanalization for the left CCA and the stent was clearly seen in the gross specimen (Figures 1F–H), and the 6-month postoperative CTA showed persistent patency (Figure 1I).

**Patient 9**
A 54-year-old man presented with recurrent dizziness. He later developed walking instability. DSA demonstrated left V1 occlusion 5 months after stenting (Figures 2A,B). V1 was reconstituted by collaterals from muscular and thyrocervical branches (Figure 2C). Although the right VA was dominant, the deficiency of the right posterior inferior cerebellar artery (PICA) and hypoperfusion of the left PICA resulted in recurrent and aggravating symptoms (Figures 2D,E). He underwent hybrid recanalization for the left VA and the stent was clearly seen in the gross specimen (Figures 2F,G), and the 22-month postoperative CTA showed persistent patency (Figure 2H).

**DISCUSSION**

The rates of ischemic cerebrovascular events involving the carotid bifurcations or the vertebro-basilar circulation have been estimated at 7–20% and 25%, respectively (10–13); these are considered high rates. Stenting is regarded as the preferred option for carotid and vertebral artery stenosis surgery for its low invasiveness, low patient discomfort, and short hospitalization time, among other reasons (14, 15). However, the widespread use of CAS and VAS leads to the occurrence of early and late complications, like ISR or ISO. The benefits of stenting in the prevention of future stroke may be hampered by the high rate of ISR or ISO (2, 16). In our study, we presented a hybrid recanalization treatment in 12 patients with carotid or vertebral ISR/ISO with good follow-up results. In addition, the illustrative cases demonstrate the challenges that a neurosurgeon or neurointerventionalist can face when managing such cases.

ISR has been defined by an angiography cutoff value of ≥50 or ≥70% in several studies (3, 5, 15). We used the latter as our standard in all cases after angiographic calculation. Duplex ultrasonography also correlated very well with catheter-based angiography. Peak systolic velocity (PSV) of 300 cm/s, end-diastolic velocity (EDV) of 140 cm/s, and ICA/CCA of 3.8 are, as well, optimal cutoff points to detect 70% restenosis after stenting (17, 18).

With respect to the pathogenesis of this process, early ISR (<6 weeks) is caused by myointimal hyperplasia and vascular remodeling, and late ISR is a consequence of recurrent neatherosclerosis (19, 20). Compared with VA plaques, ICA plaques were more prone to eccentric lesions; this was largely due to less shear stress on the lateral wall, where most plaques occurred (21, 22). Stent fracture has also been previously reported to predict plaque formation due to abnormal endothelial proliferation caused by mechanical disruption of the fracture. An incidence of stent fracture up to 4–25% has been reported in previous studies, but the stent fracture incidence in our cohort was lower, probably due to the specific inclusion criteria (23).

The risk factors for ISR may originate from three sources: the patients, physician skill, and stent characteristics (5, 24, 25). The first source includes factors such as smoking, hypertension, hyperlipidemia, atrial fibrillation, diabetes mellitus, C-reactive protein (>5 mg/l), and coronary artery disease. These could be controlled by pharmacological and lifestyle management (5, 24). The second source includes high postoperative residual stenosis caused by the lack of skill of the surgeon. A high degree of residual stenosis with a corresponding small vascular diameter is an independent risk factor for ISR, and technical success is mostly defined as residual stenosis < 30% (24). Finally, the third source includes a small stent diameter, which is consistent with a small artery size and has been reported as another predictor of ISR (25).

Standard pharmacological management of ISR— including antiplatelet, statin, and antihypertensive drugs— is the first step before further treatment (2, 5). The efficacy of medication in reducing the long-term stroke risk remains controversial.
FIGURE 2 | (A) Severe stenosis of the left vertebral artery (VA) ostium was observed in the digital subtraction angiography (DSA). (B) Revascularization was achieved with balloon and stent angioplasty. (C) DSA showed recurrent left V1 occlusion at the 5 months follow-up. (D) Intraoperative angiography demonstrated dominant right VA with the deficiency of ipsilateral PICA. (E) Intraoperative angiography also demonstrated symptomatic non-dominant left VA with a thin posterior inferior (Continued)
The Vertebral Artery Ischemic Stenting Trial (VIST) showed that pharmacological treatment was preferred in cases of intracranial vertebral stenosis because of high operative risk; the Vertebral Artery Stenting Trial (VAST) demonstrated a higher same territory stroke risk in the stented group than in the pharmacological treatment group (26, 27). However, the Warfarin–Aspirin Symptomatic Intracranial Disease (WASID) study group concluded that many patients with symptomatic VA ostium disease continued to have ischemic events despite optimal pharmacological therapy. A previous study also demonstrated that recurrent symptoms still appeared in patients treated with maximal pharmacological therapy, and 18% of the ICA stenosed patients developed a severe disability or died during the follow-up (28, 29).

Endovascular treatment mainly included balloon or stent angioplasty. Balloon is considered preferable to stent angioplasty because of its higher patency rates during short-term follow-up and because of the challenge of passing the catheter through the in-stent restenosis (5). However, multiple studies have demonstrated a trend toward choosing stenting over balloon angioplasty for its lower restenosis rates during long-term follow-up (30, 31). Different types of the stent also resulted in different ISR rates. A prospective randomized trial reported a lower ISR rate of 3.1% in the self-expanding stent group compared with 22.9% in the balloon-expandable stent group; the favorable outcome of the self-expanding stent is likely due to its flexibility and compliance to the tortuous vessels. Previous studies have also shown that drug-eluting stents were associated with a lower restenosis rate (11%) than were bare metal stents (19.4–30%) due to their ability to inhibit endothelial proliferation (32, 33).

Surgical revascularization includes primary endarterectomy, transposition, and a hybrid technique. CEA is a conventional treatment that can remove plaque with a stent, while VEA is not widely used due to its technical challenge and the lack of supporting findings from randomized trials (6, 7). VA transposition is a good alternative treatment for proximal VA occlusive disease, but it is difficult to achieve recanalization of the distal VA (1). Therefore, a hybrid technique that combines endarterectomy and endovascular intervention has emerged as an alternative procedure to achieve recanalization, especially for long-segmental occlusion. Open surgery could not only obtain proximal revascularization but also make the real lumen (the interface between the plaque and vessel wall) visible (7, 34). A technique reported in previous studies was the insertion of a microwire into the real lumen of the VA to ensure the completion of subsequent thrombectomy and stenting (6, 35). However, considering the mostly straight anatomy of the proximal ICA and the V1 segment and the performance of preoperative angiography evaluation, the Fogarty balloon was directly inserted through the exposed proximal ICA or V1 segment to conduct the surgical thrombectomy in our center.

In addition, complementary endovascular thrombectomy or stenting could also achieve distal recanalization and avoid destroying the collaterals from the thyrocervical or costocervical trunk (35). In addition to wound hematomas and infections, Horner syndrome and chylothorax are inherent risks of the process of VA endarterectomy and transposition (1, 7). In our study, two patients in the VAS group developed transient nerve dysfunction after surgery, whereas none of the CAS group developed this complication. These were two main reasons for this disparity. First, the endarterectomy required a delicate operative maneuver under the microscope. Second, the operation area of CEA was almost limited to the carotid sheath after it was cut open, observing little injury to the cranial nerve. In addition, the surgical ligation of the left thoracic duct was performed to prevent postoperative chylothorax in VA hybrid recanalization.

This study had several limitations. To begin with, it was a retrospective, small sample size, single-center design, and one hybrid technique study. Furthermore, a longer and sufficient follow-up including cranial MRI, is needed to evaluate neurologic improvement, the patency of the recanalized ICA or VA, and the efficacy of hybrid surgery. Prospective multicenter randomized control and larger sample size studies are needed to confirm the safety and efficacy of hybrid recanalization strategy.

Symptomatic post-stenting restenosis or occlusion of ICA or VA stenosis poses a challenging dilemma to neurosurgeons and neurointerventional radiologists. Symptomatic patients with post-stent restenosis or occlusion of the ICA or the VA refractory to pharmacological treatment are candidates for a revascularization procedure. The present study demonstrates that a hybrid procedure for ICA and VA post-stenting restenosis or occlusion maybe a feasible treatment strategy. A large sample size and long-term follow-up are necessary to confirm these findings.

CONCLUSION

A hybrid technique that combines endarterectomy and endovascular intervention maybe a safe and feasible treatment option to recanalize in-stent restenosis or occlusion with acceptable complications.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics committee of Qilu hospital...
of Shandong University (KYL-2020(KS)-533). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

DW and XL made substantial contributions to the conception and design of the work. The Operation and data acquisition were performed by PZ, TS, and MH. YW and WW performed the data analysis. CW drafted the manuscript and all of the other authors revised it critically for important intellectual content. All authors read and approved the final version to be published and they agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

REFERENCES

1. Hanel RA, Brasilienne LC, Spetzler RF. Microsurgical revascularization of proximal vertebral artery: a single-center, single-operator analysis. Neurosurgery. (2009) 64:1043–50. doi: 10.1227/01.NEU.000034799.17537.64
2. Pourier VE, de Borst GJ. Technical options for treatment of in-stent restenosis after carotid artery stenting. J Vasc Surg. (2016) 64:1486–96. doi: 10.1016/j.vasc.2016.07.106
3. Yu LB, Yan W, Zhang Q, Zhao JZ, Zhang Y, Wang R, et al. Carotid endarterectomy for treatment of carotid in-stent restenosis: long-term follow-up results and surgery experiences from one single centre. Stroke Vasc Neur. (2017) 2:140–6. doi: 10.1136/ste-2017-000089
4. Qiu ZH, Ma Y, Lu X, Gao P, Jiao LQ, Ling F. Hybrid recanalization for symptomatic long-segmental occlusion post vertebral artery stenting. Catheter Cardiovasc Interv. (2020) 96:404–9. doi: 10.1002/ccd.28906
5. Wolska-Krawczyk M, Drunck M, Behnke S, Reith W. Risk factors for restenosis after stenting or angioplasty of vertebral artery origin: results of short-term and long-term follow-up. Clin Neurorad. (2020) 30:355–62. doi: 10.1055/s-0040-170898
6. Yang B, Ma Y, Lu X, Gao P, Jiao LQ, Ling F. Hybrid recanalization for symptomatic long-segmental occlusion post vertebral artery stenting. World Neurosurg. (2018) 110:349–53. doi: 10.1016/j.wneu.2017.11.081
7. Lu X, Ma Y, Yang B, Gao P, Wang Y, Jiao LQ. Hybrid technique for the treatment of refractory vertebrobasilar insufficiencies. World Neurosurg. (2017) 107:e13–7. doi: 10.1016/j.wneu.2017.08.081
8. Zanaty M, Roa JA, Jabbour PM, Samaniego EA, Hasan DM. Recanalization of the chronically occluded internal carotid artery: review of the literature. World Neurosurg. (2019) 5:100067. doi: 10.1016/j.wnsx.2019.100067
9. Yang YN, Liu XJ, Wang R, Zhang Y, Zhang D, Zhao JZ. A treatment option for symptomatic chronic complete internal carotid artery occlusion: hybrid surgery. Front Neurosci. (2020) 14:392. doi: 10.3389/fnins.2020.00392
10. Chaturvedi S, Sacco RL. How recent data have impacted the treatment of internal carotid artery stenosis. J Am Coll Cardiol. (2015) 65:1134–43. doi: 10.1016/j.jacc.2014.12.045
11. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. ASA/ACCC/AHA/AANN/AANS/ACR/ASNR/CNS/SAPI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke. (2011) 42:e464–540. doi: 10.1161/STR.0b013e3182112cc2
12. Moulin T, Tatu L, Vuillier F, Berger E, Chavot D, Rumbach L. Role of a stroke data bank in evaluating cerebral infarction subtypes: patterns and outcome of 1,776 consecutive patients from the Besançon stroke registry. Cerebrovasc Dis. (2000) 10:261–71. doi: 10.1159/000016068
13. Vemmos KN, Takis CE, Georgilis K, Zakopoulos NA, Lekakis JP, Papamichael CM, et al. The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis. (2000) 10:133–41. doi: 10.1159/000016042
14. Cohen DJ, Stolker JM, Wang K, Magnusson EA, Clark WM, Damaerschalk BM, et al. Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). J Am Coll Cardiol. (2011) 58:1557–65. doi: 10.1016/j.jacc.2011.05.054
15. Dai ZZ, Xu GL. Restenosis after carotid artery stenting. Vascular. (2017) 25:576–86. doi: 10.1177/1708538117706273
16. de Borst GJ, Ackerstaff RG, de Vries JP, vd Pavordt ED, Vos JA, Overtoom TT, et al. Carotid angioplasty and stenting for postendarterectomy stenosis: long-term follow-up. J Vasc Surg. (2005) 42:118–23. doi: 10.1016/j.vasc.2006.09.013
17. Zapata-Arriaza E, Moniche F, Gonzalez A, Bustamante A, Escudero-Martínez I, De la Torre Laviana FJ, et al. Predictors of restenosis following carotid angioplasty and stenting. Stroke. (2016) 47:2114–7. doi: 10.1161/STROKEAHA.116.012650
18. Wasser K, Schnaudigel S, Wohlfahr J, Psychogios MN, Schramm P, Knauth M, et al. Clinical impact and predictors of carotid artery in-stent restenosis. J Neurol. (2012) 259:1896–902. doi: 10.1007/s00412-015-0643-3
19. Gröschel K, Riecker A, Schulz JB, Ermenmann U, Kastrup A. Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke. (2005) 36:367–73. doi: 10.1161/01.STR.0000152357.82843.9F
20. Clark DJ, Lessio S, O’Donoghue M, Tsalamandris C, Schainfeld R, Rosenfeld K. Mechanisms and predictors of carotid artery stent restenosis: a serial intravascular ultrasound study. J Am Coll Cardiol. (2006) 47:2390–9. doi: 10.1016/j.jacc.2006.01.076
21. Simonetto M, DeSousa K, Campo N, Pandey V, Koch S. Topography of vertebral artery origin plaques. J Ultrasound Med. (2019) 38:331–5. doi: 10.1002/jum.14692
22. Densl NP, van der Wal AC, Ritzen K, de Boer OJ, Aronica E, Troost D, et al. Atherosclerosis in the circle of Willis: spatial differences in composition and in distribution of plaques. Atherosclerosis. (2016) 251:78–84. doi: 10.1016/j.atherosclerosis.2016.05.047
23. Li MKA, Tsang ACO, Tsang FCP, Ho WS, Lee R, Leung GKK, et al. Long-term risk of in-stent restenosis and stent fracture for extracranial vertebral artery stenting. Clin Neuroradiol. (2019) 29:701–6. doi: 10.1007/s00062-018-0708-y

FUNDING

This work was supported by the National Natural Science Foundation of China (81972351 and 81702474), the Department of Science & Technology of Shandong Province (2017CXGC1502, 2018CXGC1503, and 2018GSF118082), the Special Foundation of Taishan Scholars (ts20110814), the Clinical Practical New Technology Development Foundation of Qiliu Hospital (grant 2019-7), the Natural Science Foundation of Shandong Province (ZR2017LH033), and the Scientific Research Foundation of Binzhou Medical University (BY2016KYQD15).

ACKNOWLEDGMENTS

The authors acknowledge assistance from the Endovascular Neurosurgery Research Group members (Department of Neurosurgery, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, China). We thank Editage (www.editage.cn) for editing the English text of a draft of the manuscript.
Wang et al. Hybrid Recanalization for In-stent Restenosis

24. Dai Z, Zhu MY, Shi W, Li M, Chen WH, Dai QL, et al. The incidence and risk factors of in-stent restenosis for vertebrobasilar artery stenting. World Neurosurg. (2018) 110:e937–41. doi: 10.1016/j.wneu.2017.11.112

25. Kornowski R, Fort S, Almagor Y, Silber S, Lewis BS, Nirtop Investigators. Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: insights from the NIRTOP study. Acute Card Care. (2008) 10:104–10. doi: 10.1080/17482940701787754

26. Markus HS, Larsson SC, Kuker W, Schulz UG, Ford I, Rothwell PM, et al. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. Neurology. (2017) 89:1229–36. doi: 10.1212/WNL.0000000000004385

27. Compter A, van der Worp HB, Schonewille WJ, Vos JA, Boiten J, Nederkoorn PJ, et al. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol. (2015) 14:606–14. doi: 10.1016/S1474-4422(15)00017-4

28. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) study group. Stroke. (1998) 29:1389–92. doi: 10.1161/01.STR.29.7.1389

29. Muller-Kuppers M, Graf KJ, Pessin MS, DeWitt LD, Caplan LR. Intracranial vertebral artery disease in the new england Medical Center posterior circulation registry. Eur Neurol. (1997) 37:46–56. doi: 10.1159/000117427

30. Wang J, Zhong CY, Zhang Y, Wei YN, Liu HL, Wu CL, et al. Seven years' follow-up of comparative study between stenting and medication for treatment of symptomatic vertebrobasilar artery stenosis. Interv Neuroradiol. (2017) 23:43–50. doi: 10.1177/159101991776032

31. Antoniou GA, Murray D, Georgiadis GS, Antoniou SA, Serracino-Inglott F, et al. Percutaneous transluminal angioplasty and stenting in patients with proximal vertebral artery stenosis. J Vasc Surg. (2012) 55:1167–77. doi: 10.1016/j.vasu.2011.09.084

32. Geng X, Hussain M, Du H, Zhao L, Chen J, Su W, et al. Comparison of self-expanding stents with distal embolic protection to balloon-expandable stents without a protection device in the treatment of symptomatic vertebral artery origin stenosis: a prospective randomized trial. J Endovasc Ther. (2015) 22:436–44. doi: 10.1177/1526602815579406

33. Jiang YJ, Xu XM, Wen ZY, Xu XH, Yang L, Liu XF. In-stent restenosis after vertebral artery stenting. Int J Cardiol. (2015) 187:430–3. doi: 10.1016/j.ijcard.2015.03.377

34. Shih YT, Chen WH, Lee WL, Lee HT, Shen CC, Tsuei YS. Hybrid surgery for symptomatic chronic total occlusion of carotid artery: a technical note. Neurosurgery. (2013) 73:onsE17–23. doi: 10.1227/NEU.0b013e31827fc6c

35. Ma Y, Yang B, Lu X, Gao P, Jiao LQ, Ling F. Safety and blood-flow outcomes for hybrid recanalization in symptomatic refractory long-segmental vertebral artery occlusion-results of a pilot study. Front Neurol. (2020) 11:387. doi: 10.3389/fneur.2020.00387

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer MZ declared a shared affiliation with the authors to the handling editor at time of review.

Copyright © 2020 Wang, Zhao, Sun, Han, Wang, Wu, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.